Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma

被引：9
作者：
Benjamin, David J. [1 ]
Mar, Nataliya [2 ]
Kalebasty, Arash Rezazadeh [2 ]
机构：
[1] Hoag Family Canc Inst, Med Oncol, Newport Beach, CA USA
[2] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Med, Div Hematol & Oncol, 101 City Dr South,Bldg 200, Orange, CA 92668 USA
来源：
CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2022年 / 16卷
关键词：
Urothelial carcinoma; bladder cancer; FGFR; erdafitinib; checkpoint inhibitor; immunotherapy; THERAPY; OPPORTUNITIES; ERDAFITINIB; EFFICACY; SUBTYPES;
D O I：
10.1177/11795549221126252
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC. In addition. recent molecular characterization of bladder cancer has revealed several subtypes. including those harboring fibroblast growth factor receptor (FGFR) mutations and fusion proteins. Erdafitinib, a pan-FGFR inhibitor, was approved for the treatment of metastatic/advanced UC in 2019. Some available evidence suggests ICI may have inferior response in advanced FGFR+ UC for unclear reasons, but may possibly be related to the tumor microenvironment. Several ongoing trials are evaluating erdafitinib in metastatic/advanced UC including the ongoing phase IB/II NORSE trial combining erdafitinib plus ICI, which may prove to offer a more robust and durable response in patients with FGFR+ metastatic/advanced UC.
引用
收藏
页数：5
相关论文
共 35 条
[1]  
[Anonymous], 2022, COLD HOT TUM
[2]  
[Anonymous], 2022, INTR LAYOUT END RET
[3]  
[Anonymous], 2019, News release
[4]  
[Anonymous], Treatment by Cancer Type
[5]   Advances and challenges in targeting FGFR signalling in cancer [J].
Babina, Irina S. ;
Turner, Nicholas C. .
NATURE REVIEWS CANCER, 2017, 17 (05) :318-332
[6]   Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG). [J].
Balar, Arjun Vasant ;
Kulkarni, Girish S. ;
Uchio, Edward M. ;
Boormans, Joost ;
Mourey, Loic ;
Krieger, Laurence Eliot Miles ;
Singer, Eric A. ;
Bajorin, Dean F. ;
Kamat, Ashish M. ;
Grivas, Petros ;
Seo, Ho Kyung ;
Nishiyama, Hiroyuki ;
Konety, Badrinath R. ;
Nam, Kijoeng ;
Kapadia, Ekta ;
Frenkl, Tara L. ;
De Wit, Ronald .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[7]   The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience [J].
Bambury, Richard M. ;
Benjamin, David J. ;
Chaim, Joshua L. ;
Zabor, Emily C. ;
Sullivan, John ;
Garcia-Grossman, Ilana R. ;
Regazzi, Ashley M. ;
Ostrovnaya, Irina ;
Apollo, Aryln ;
Xiao, Han ;
Voss, Amartin H. ;
Iyer, Gopa ;
Bajorin, Dean F. ;
Rosenberg, Jonathan E. .
ONCOLOGIST, 2015, 20 (05) :508-515
[8]   Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract [J].
Bellmunt, Joaquim ;
Theodore, Christine ;
Demkov, Tomasz ;
Komyakov, Boris ;
Sengelov, Lisa ;
Daugaard, Gedske ;
Caty, Armelle ;
Carles, Joan ;
Jagiello-Gruszfeld, Agnieszka ;
Karyakin, Oleg ;
Delgado, Francois-Michel ;
Hurteloup, Patrick ;
Morsli, Nassim ;
Salhi, Yacine ;
Culine, Stephane ;
von der Maase, Hans .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4454-4461
[9]   Epidemiology and Risk Factors of Urothelial Bladder Cancer [J].
Burger, Maximilian ;
Catto, James W. F. ;
Dalbagni, Guido ;
Grossman, H. Barton ;
Herr, Harry ;
Karakiewicz, Pierre ;
Kassouf, Wassim ;
Kiemeney, Lambertus A. ;
La Vecchia, Carlo ;
Shariat, Shahrokh ;
Lotan, Yair .
EUROPEAN UROLOGY, 2013, 63 (02) :234-241
[10]  
Calles Antonio, 2020, Am Soc Clin Oncol Educ Book, V40, P372, DOI 10.1200/EDBK_280795
1234